Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Healios

ヘリオス

4593 · TSE · Pharmaceutical · 1 article

Financials Consolidated

Revenue¥104m−81.4% year on yearConsolidated · FY12/25

Operating profit−¥3.34bnConsolidated · FY12/25

Net profit−¥2.22bnConsolidated · FY12/25

Performance over time

Revenue
¥41.0mFY12/21
¥90.0mFY12/22
¥121mFY12/23
¥560mFY12/24
¥104mFY12/25
Net profit (attributable)
−¥4.91bnFY12/21
−¥5.17bnFY12/22
−¥3.82bnFY12/23
−¥4.24bnFY12/24
−¥2.22bnFY12/25
Op. cash flow
−¥5.09bnFY12/21
−¥4.60bnFY12/22
−¥2.82bnFY12/23
−¥1.82bnFY12/24
−¥3.17bnFY12/25

People & pay

Employees, whole group75 peopleFY12/25

Employees, parent company (non-consolidated)66 peopleFY12/25

Average salary¥9.12mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOp. profitNet profit (attributable)EPSTotal assetsTotal equityOp. cash flow
FY12/25¥104.0m−81.4% year on year−¥3.34bn−¥2.22bn−¥20.59¥17.1bn¥4.90bn−¥3.17bn
FY12/24¥560.0m+362.8% year on year−¥2.84bn−¥4.24bn−¥47.86¥14.2bn¥2.08bn−¥1.82bn
FY12/23¥121.0m+34.4% year on year—−¥3.82bn−¥56.22¥15.2bn¥3.87bn−¥2.82bn
FY12/22¥90.0m+119.5% year on year—−¥5.17bn−¥90.67¥15.0bn—−¥4.60bn
FY12/21¥41.0m—−¥4.91bn−¥93.36¥24.0bn—−¥5.09bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XTBP · IFRS. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4593

Tokyo Brief coverage

  1. Helios ties paid option grants to ARDS approval and a ¥1.5bn sales hurdle

    The 29th option series can be exercised only if Helios wins domestic approval for HLCM051 in ARDS and records at least ¥1.5bn of revenue in any year through 2032. Full exercise would equal 9.0% of shares outstanding, while the same-day 28th, 29th and 30th series together reach 14.0% dilution.

All articles loaded · 1 shown

5% holders

Latest disclosed holders and exits below 5%.

1 holder · data through

No stored data for this selection.

Exits below 5%

Exits below 5%
HolderStakeChangePurposeFiling
Morgan Stanley & Co. International plc
Original (Japanese)モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー
3.87% own · 3.87% group of 2−1.52 ppBroker-dealer inventoryHeld for securities business, etc.Machine translated
Original (Japanese)証券業務等にかかる保有
Filed  — filing S100ZCJB

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

6 fiscal years · data through

Balance-sheet value
¥2.95bnFY12/20
¥1.69bnFY12/21
¥0.07bnFY12/22
—FY12/23

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 2025No listed strategic holdings reported————Filed 
Show 5 more fiscal years (6 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 2024No listed strategic holdings reported————Filed 
31 Dec 2023———1¥30mFiled  — filing S100T62O
31 Dec 20221¥73m1.67%——Filed  — filing S100QHOQ
31 Dec 20211¥1.69bn19.53%——Filed  — filing S100NRBI
31 Dec 20201¥2.95bn37.63%——Filed  — filing S100L2DY

Fund positioning

Current holdings disclosed by tracked funds.

1 fund · data through

Held by 1 tracked fund; largest weight 0.36%. Holdings as of 19 Nov 2026.

Fund positioning
FundNAV weight
TSE Growth 250 ETF0.36%